Grace Therapeutics, Inc.

TSXV:ACST Stock Report

Market Cap: CA$19.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acasti Pharma Management

Management criteria checks 0/4

Key information

Jan D'Alvise

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage25.1%
CEO tenure6.8yrs
CEO ownership0.01%
Management average tenure1.6yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Mar 01
Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Aug 17
Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Jan 12
Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Jan D'Alvise's remuneration changed compared to Acasti Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022US$2mUS$445k

-US$10m

Dec 31 2021n/an/a

-US$12m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021US$582kUS$428k

-US$20m

Dec 31 2020n/an/a

US$3m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020US$2mUS$411k

-US$26m

Dec 31 2019n/an/a

-US$56m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019US$926kUS$373k

-US$39m

Dec 31 2018n/an/a

-US$31m

Sep 30 2018n/an/a

-US$34m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018US$891kUS$337k

-US$17m

Mar 31 2017US$631kUS$275k

-US$8m

Compensation vs Market: Jan's total compensation ($USD1.77M) is above average for companies of similar size in the Canadian market ($USD172.33K).

Compensation vs Earnings: Jan's compensation has increased whilst the company is unprofitable.

CEO

Jan D'Alvise (67 yo)

6.8yrs

Tenure

US$1,773,841

Compensation

Ms. Janelle D’Alvise, also known as Jan, has been an Independent Director of Spectral Medical Inc. since June 03, 2021. She is the Chairman of the board of The ObG Project. She has been the Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Janelle D'Alvise
President6.8yrsUS$1.77m0.015%
CA$ 2.8k
Pierre Lemieux
Co-Founder12.9yrsUS$905.45k0.0020%
CA$ 377.0
Brian Ford
Chief Financial Officer2.5yrsUS$847.55k0%
CA$ 0
George Kottayil
Chief Operating Officer of US1.6yrsUS$666.86k0%
CA$ 0
Prashant Kohli
Chief Commercial Officer1.2yrsUS$403.62k0.29%
CA$ 55.2k
Yves Lachance
Vice President of Quality & Compliance1.5yrsno datano data
Christine Pelletier
Senior Director of Human Resources1.2yrsno datano data

1.6yrs

Average Tenure

61yo

Average Age

Experienced Management: ACST's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Janelle D'Alvise
President6.7yrsUS$1.77m0.015%
CA$ 2.8k
Donald Olds
Independent Director4.9yrsUS$131.60k0.011%
CA$ 2.0k
Michael Derby
Independent Director1yrUS$6.00kno data
Jean-Marie Canan
Independent Director6.7yrsUS$134.10k0.028%
CA$ 5.4k
R. MacDonald
Member of Scientific Advisory Boardless than a yearno datano data
Vimal Kavuru
Independent Director1.6yrsUS$96.60k0%
CA$ 0
Dariush Mozaffarian
Member of Scientific Advisory Boardno datano datano data
Andrew Ducruet
Member of Scientific Advisory Boardless than a yearno datano data
Alex Choi
Member of Scientific Advisory Board1.2yrsno datano data

1.4yrs

Average Tenure

61yo

Average Age

Experienced Board: ACST's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/29 07:06
End of Day Share Price 2023/03/27 00:00
Earnings2022/12/31
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grace Therapeutics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeByron Capital Markets